Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 349602, 6 pages
http://dx.doi.org/10.1155/2014/349602
Research Article

Urinary Angiotensinogen Is Elevated in Patients with Nephrolithiasis

1Department of Urological Surgery, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China
2Department of Nephrology, Affiliated Drum Tower Hospital, Nanjing University, Nanjing, Jiangsu 210093, China

Received 4 February 2014; Accepted 19 March 2014; Published 9 April 2014

Academic Editor: John J. Gildea

Copyright © 2014 Wei Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Keddis and A. D. Rule, “Nephrolithiasis and loss of kidney function,” Current Opinion in Nephrology & Hypertension, vol. 22, no. 4, pp. 390–396, 2013. View at Publisher · View at Google Scholar
  2. A. Neisius and G. M. Preminger, “Stones in 2012: epidemiology, prevention and redefining therapeutic standards,” Nature Reviews Urology, vol. 10, no. 2, pp. 75–77.
  3. S. R. Khan, “Role of renal epithelial cells in the initiation of calcium oxalate stones,” Nephron—Experimental Nephrology, vol. 98, no. 2, pp. e55–e60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Moonen, V. Fraipont, L. Radermacher, C. Masset, É. Firre, and X. Warling, “Acute kidney injury: from concept to practice,” Nephrologie et Therapeutique, vol. 7, no. 3, pp. 172–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. W. Batenburg and A. H. Danser, “(Pro)renin and its receptors: pathophysiological implications,” Clinical Science, vol. 123, no. 3, pp. 121–133, 2012. View at Publisher · View at Google Scholar
  6. L. G. Navar, M. C. Prieto, R. Satou, and H. Kobori, “Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension,” Current Opinion in Pharmacology, vol. 11, no. 2, pp. 180–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Kim, H. R. Jang, Y.-J. Lee et al., “Urinary angiotensinogen levels reflect the severity of renal histopathology in patients with chronic kidney disease,” Clinical Nephrology, vol. 76, no. 2, pp. 117–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. W. H. Yiu, C.-J. Pan, R. A. Ruef et al., “Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia,” Kidney International, vol. 73, no. 6, pp. 716–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Kamiyama, M. Urushihara, T. Morikawa et al., “Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 23045–23062, 2013. View at Publisher · View at Google Scholar
  11. J. L. Alge, N. Karakala, B. A. Neely, M. G. Janech, J. C. Velez, and J. M. Arthur, “Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit,” Critical Care, vol. 17, no. 2, article R69, 2013. View at Google Scholar
  12. M. Decoster, J. C. Bigot, J. L. Carre et al., “Epidemiologic study of urinary calculi in Western France,” Presse Medicale, vol. 31, no. 3, pp. 113–118, 2002. View at Google Scholar · View at Scopus
  13. T. Terami, J. Wada, K. Inoue et al., “Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes,” International Journal of Nephrology and Renovascular Disease, vol. 6, pp. 233–240, 2013. View at Google Scholar
  14. H. Kobori, L. M. Harrison-Bernard, and L. G. Navar, “Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production,” Kidney International, vol. 61, no. 2, pp. 579–585, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Kobori, A. Nishiyama, L. M. Harrison-Bernard, and L. Gabriel Navar, “Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension,” Hypertension, vol. 41, no. 1, pp. 42–49, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. H. M. Siragy and R. M. Carey, “Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease,” American Journal of Nephrology, vol. 31, no. 6, pp. 541–550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. T. W. Hsu, J. S. Liu, S. C. Hung et al., “Renoprotective effect of Renin-Angiotensin-Aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia,” Journal of the American Medical Association Internal Medicine, vol. 174, no. 3, pp. 347–354, 2014. View at Publisher · View at Google Scholar
  18. J. L. Alge, N. Karakala, B. A. Neely et al., “Urinary angiotensinogen and risk of severe AKI,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 2, pp. 184–193, 2013. View at Publisher · View at Google Scholar
  19. L. C. Roksnoer, K. Verdonk, A. H. van den Meiracker, E. J. Hoorn, R. Zietse, and A. H. Danser, “Urinary markers of intrarenal renin-angiotensin system activity in vivo,” Current Hypertension Reports, vol. 15, no. 2, pp. 81–88, 2013. View at Publisher · View at Google Scholar
  20. M. van den Heuvel, W. W. Batenburg, S. Jainandunsing et al., “Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney,” Journal of Hypertension, vol. 29, no. 11, pp. 2147–2155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-Y. Hong, K. Hughes, K.-S. Chia, V. Ng, and S.-L. Ling, “Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore,” Diabetes Care, vol. 26, no. 2, pp. 338–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Petrica, M. Petrica, A. Vlad et al., “Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study,” Nephron—Clinical Practice, vol. 118, no. 2, pp. c155–c164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Igci, A. Arslan, Y. Z. Igci et al., “Bikunin and α1-microglobulin/bikunin precursor (AMBP) gene mutational screening in patients with kidney stones: a case-control study,” Scandinavian Journal of Urology and Nephrology, vol. 44, no. 6, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. P. Richoux, J. L. Cordonnier, J. Bouhnik et al., “Immunocytochemical localization of angiotensinogen in rat liver and kidney,” Cell and Tissue Research, vol. 233, no. 2, pp. 439–451, 1983. View at Google Scholar · View at Scopus
  25. M. Kamiyama, A. Zsombok, and H. Kobori, “Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes,” Journal of Pharmacological Sciences, vol. 119, no. 4, pp. 314–323, 2012. View at Publisher · View at Google Scholar
  26. R. A. Gonzalez-Villalobos, T. Janjoulia, N. K. Fletcher et al., “The absence of intrarenal ACE protects against hypertension,” The Journal of Clinical Investigation, vol. 123, no. 5, pp. 2011–2023, 2011. View at Google Scholar